Product image of Migoutine (Colchicine) supplied by GNH India

Migoutine

Active Ingredient:
Colchicine
Origin:
EU

Migoutine (Colchicine)

Colchicine, the active ingredient in Migoutine, is an alkaloid (microtubule inhibitor) presented as an oral tablet for oral use. It reduces inflammation during acute gout flares, helps prevent recurrent gout attacks, and is used for long‑term management of familial Mediterranean fever in adult patients.

GNH India supplies Migoutine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards. The product complies with EU pharmacopeial specifications and is available for bulk procurement.

Manufacturer / TM Owner

Zentiva France

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Colchicine is used to manage inflammatory conditions related to crystal deposition and hereditary autoinflammatory disorders.
  • Acute gout flares: rapid reduction of joint inflammation and pain during an attack.
  • Prophylaxis of gout attacks: prevention of recurrent gout episodes when used continuously.
  • Familial Mediterranean fever: control of febrile attacks and serosal inflammation in affected individuals.

How It Works

  • Colchicine binds to tubulin at the colchicine‑binding site, preventing microtubule polymerisation. This disrupts neutrophil motility, chemotaxis and degranulation, thereby limiting the inflammatory response to monosodium urate crystals and other triggers. The inhibition of microtubule assembly also interferes with inflammasome activation, reducing interleukin‑1β release. By stabilising the cytoskeleton, colchicine also impairs leukocyte adhesion and migration, contributing to its overall anti‑inflammatory effect in gout and FMF.

Side Effects

Colchicine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, abdominal pain, or diarrhoea.
  • Diarrhoea: frequent loose stools, sometimes leading to dehydration.
  • Abdominal cramping: discomfort in the stomach area.
  • Loss of appetite: reduced desire to eat.
  • Headache: mild to moderate head pain.
  • Metallic taste: altered taste sensation.

Serious or Rare Side Effects

  • Myelosuppression: bone‑marrow depression causing low blood counts.
  • Neuromuscular toxicity: muscle weakness or neuropathy, especially with renal impairment.
  • Severe hypersensitivity: rash, fever, or anaphylaxis.
  • Multi‑organ failure: rare but life‑threatening systemic toxicity.

Precautions & Warnings

  • When prescribing colchicine, clinicians should consider several precautionary measures to minimise risk.
  • Renal function: adjust dose or avoid use in severe renal impairment.
  • Hepatic function: monitor liver enzymes and use caution in hepatic disease.
  • Drug interactions: review concomitant medications that affect colchicine metabolism.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Gastrointestinal disorders: use with caution in patients with pre‑existing GI disease.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Avoid Interactions

Colchicine interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause colchicine toxicity.
  • P‑glycoprotein inhibitors (e.g., cyclosporine, verapamil): increase colchicine levels.
  • Statins (especially simvastatin) at high doses: risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely)

  • Digoxin: colchicine may increase digoxin concentrations.
  • Macrolide antibiotics (e.g., azithromycin): moderate increase in colchicine exposure.
  • NSAIDs: additive gastrointestinal irritation risk.

Frequently Asked Questions

Migoutine contains colchicine, which is indicated for the treatment of acute gout flares, for prophylaxis to reduce the frequency of gout attacks, and for long‑term management of familial Mediterranean fever, an inherited autoinflammatory disorder.

Colchicine binds to tubulin, blocking microtubule formation. This impairs neutrophil movement and activation, reduces chemotaxis and degranulation, and limits the release of inflammatory mediators such as interleukin‑1β, thereby decreasing inflammation associated with gout crystals and FMF attacks.

The dosing regimen for Migoutine is determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and other individual factors. Healthcare professionals should follow current clinical guidelines and adjust the dose as needed.

Safety data for colchicine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk to the fetus or infant.

To order Migoutine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternatives for acute gout are non‑steroidal anti‑inflammatory drugs (NSAIDs) and corticosteroids. Compared with NSAIDs, colchicine has a different mechanism—targeting neutrophil activity rather than cyclo‑oxygenase inhibition—and may be preferred when NSAIDs are contraindicated or poorly tolerated. Allopurinol, a urate‑lowering therapy, is used for chronic management rather than acute attacks.

Migoutine should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Migoutine is taken orally as a tablet with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals to minimise gastrointestinal upset.

Serious adverse events include myelosuppression (low blood cell counts), neuromuscular toxicity such as muscle weakness or peripheral neuropathy, severe hypersensitivity reactions, and, in rare cases, multi‑organ failure. Patients should seek immediate medical attention if they experience unexplained bruising, persistent weakness, rash, fever, or signs of infection.

Migoutine is contraindicated in patients with severe renal or hepatic impairment, known hypersensitivity to colchicine, and in individuals taking strong CYP3A4 or P‑gp inhibitors that cannot be discontinued. Caution is also advised for patients with pre‑existing gastrointestinal disease, myopathy, or those who are pregnant or breastfeeding without a clear benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Colchicine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT